Eli Lilly and Company (NYSE: LLY) Stock Update

Core Insights - Eli Lilly and Company (NYSE: LLY) is recognized for its innovative drug development and healthcare solutions, with Bernstein reiterating an "Outperform" rating, indicating confidence in the company's future performance and growth potential [1][6] Investment Activity - The Bank of Montreal Can increased its stake in Eli Lilly by 8.9% during the third quarter, now holding 1,569,917 shares valued at $1.2 billion, which is approximately 0.17% of Eli Lilly's total shares [2][6] - Brighton Jones LLC raised its holdings in Eli Lilly by 22% in the fourth quarter, now owning 9,597 shares valued at $7.4 million, while Revolve Wealth Partners LLC increased its holdings by 2.8%, now possessing 1,471 shares, reflecting a broader trend of investor confidence [3] Stock Performance - Eli Lilly's stock is currently priced at $1,008.39, reflecting an increase of 1.82% or $18.06, with fluctuations between a low of $980.58 and a high of $1,008.86 during the day [4] - Over the past year, Eli Lilly's stock has reached a high of $1,133.95 and a low of $623.78, indicating volatility and potential for growth [4] - The company's market capitalization is approximately $951.27 billion, showcasing its significant presence in the pharmaceutical sector, with a trading volume of 2,016,365 shares on the NYSE [5][6]